Quick Answer
Celldex Therapeutics, Inc. reported Stockholders Equity of $527.16 million for fiscal year 2025.
Celldex Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $527.16M | -29.4% |
| 2024 | $747.00M | +74.1% |
| 2023 | $429.17M | +31.6% |
| 2022 | $326.20M | -22.2% |
| 2021 | $419.48M | +100.4% |
| 2020 | $209.36M | +122.7% |
| 2019 | $94.03M | -24.2% |
| 2018 | $124.06M | -47.5% |
| 2017 | $236.37M | -10.9% |
| 2016 | $265.43M | -8.5% |
| 2015 | $290.11M | +37.1% |
| 2014 | $211.66M | -33.8% |
| 2013 | $319.80M | +233.9% |
| 2012 | $95.77M | +39.4% |
| 2011 | $68.72M | -8.7% |
| 2010 | $75.25M | +2.0% |
| 2009 | $73.77M | +306.8% |
| 2008 | $18.13M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $598.36M | -23.9% | -8.7% |
| June 30, 2025 | $655.41M | -19.4% | -6.8% |
| March 31, 2025 | $702.98M | -16.2% | -5.9% |
| December 31, 2024 | $747.00M | +74.1% | -4.9% |
| September 30, 2024 | $785.90M | +218.5% | -3.4% |
| June 30, 2024 | $813.66M | +193.2% | -3.0% |
| March 31, 2024 | $838.61M | +177.0% | +95.4% |
| December 31, 2023 | $429.17M | +31.6% | +74.0% |
- Celldex Therapeutics, Inc. showed a decrease of -29.4% in Stockholders Equity compared to the prior fiscal year.
- Over the 2008–2025 period, Celldex Therapeutics, Inc.’s stockholders equity has grown by 2807.1% (from $18.13 million to $527.16 million).
- The most recent figure is from Celldex Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: